Abstract
The disease COVID-19 has turned out to be a tremendous slayer and has had some of the most devastating impacts on human beings ever seen in history. To overcome this major public health crisis, an understanding of the transmission of the virus underlying this disease is of paramount importance. Evidence suggests that the most common route of transmission for the SARS-CoV-2 virus is likely via direct contact in person-to-person encounter with aerosol droplets. However, the possibility of transmission via contact with fomites from surfaces is a possible route of infection as well. Environmental contamination in rooms with COVID-19 patient has been widely observed due to viral shedding from both asymptomatic and symptomatic patients. Also, in hospitals, SARS-CoV-2 is known to survive on various surfaces for extended periods of time. Because repetitive contact cycles can spread the virus from one surface to the other in healthcare settings, here we evaluated contamination on different types of surfaces commonly found in healthcare settings. Also, based on various datasets, we analyzed the importance of various surfaces in transmission modalities. Based on the findings of this study, decontamination of surfaces that frequently are in touch contact throughout all segments of the healthcare system should constitute an important part of the infection control and prevention of COVID-19. We also recommend the selection of a non-reactive disinfectant for hospital monitors, devices, ventilators and computers so that active surface disinfection can be effected without damage to the devices.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Not applicable
Funding Statement
No funding is obtained for this study
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos